The Discounted Cash Flow (DCF) valuation of Intellia Therapeutics Inc (NTLA) is (157.55) USD. With the latest stock price at 11.54 USD, the upside of Intellia Therapeutics Inc based on DCF is -1465.9%.
Based on the latest price of 11.54 USD and our DCF valuation, Intellia Therapeutics Inc (NTLA) is a sell. selling NTLA stocks now will result in a potential gain of 1465.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.3% - 6.7% | 6.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (902.81) - (88.31) | (157.55) |
| Upside | -7926.7% - -865.5% | -1465.9% |